相关实验视频

Updated: May 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

新辅助剂富祖洛帕里布与阿比拉结合用于局部高风险前列腺癌 (FAST-PC):单臂二期研究

Tingwei Zhang¹, Beihe Wang¹, Yu Wei¹

¹Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Genitourinary Cancer Institute, Shanghai, China.

Cell reports. Medicine

|March 8, 2025

概括

使用富祖洛帕里布和阿比拉的新辅助治疗在高风险前列腺癌中显示出初步的疗效,达到46%的病理完整反应或最小残留疾病率. 这种组合治疗是可行的,需要对局部性前列腺癌进行进一步的研究.

科学领域:

在瘤学瘤学.
生殖尿道癌症生殖尿道癌症
临床试验临床试验

背景情况:

临床前数据表明,雄激素受体抑制剂 (ARI) 和多氨酸二酸聚合酶 (PARP) 抑制剂之间存在协同作用.
局部高风险前列腺癌需要有效的新辅助治疗策略.

研究的目的:

为了评估新辅助剂的有效性和安全性,富祖洛巴里布 (一种PARP抑制剂) 加上阿比拉 (一种ARI) 在未经治疗的男性,局部高风险前列腺癌.
评估病理完整反应 (pCR) 和最小残留疾病 (MRD) 率作为主要终点.

主要方法:

第二期试验 (NCT05223582) 涉及35名患有局部高风险前列腺癌的男性.
患者接受了六个周期的新辅助药富祖洛帕里布加阿比拉,然后进行激进前列腺切除术.
主要终点:pCR和MRD (≤5毫米). 二级终点包括无生物化学进展生存率 (bPFS) 和安全性.

主要成果:

结合的PCR/MRD率为46% (95%CI:29%-63%),符合主要终点.
两年的bPFS率为53%.
3级以上的不良事件发生在23%的患者中. 双同源重组修复/BRCA2变化与更快的PSA下降相关.

结论:

新辅助剂富祖洛帕里布加阿比拉证明了在局部高风险前列腺癌中可行性和初步疗效.
探索性生物标志物分析表明潜在的预测标志物,并揭示治疗后的途径变化.
这些发现支持进一步研究这种组合疗法和生物标志物驱动的方法.

关键词:

前列腺癌是什么意思前列腺癌是什么意思一个是abiraterone.的子可用于制造.这是一种新辅助剂.

更多相关视频

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Published on: January 9, 2019

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...